Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant

American Journal of Transplantation

Volumn 4, Issue 8, 2004, Pages 1375-1378

  Schussler, Thomas ^a   Staffeld Coit, Catherine ^a   Eason, James ^a   Nair, Satheesh ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Hepatitis C genotype; Renal transplant

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ADULT; BIOPSY; FEMALE; GENOTYPE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; TACROLIMUS; TIME FACTORS; TRANSAMINASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 3543046181     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00504.x     Document Type: Article

References (18)

1. Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345: 484-487.
2. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States through 1994. N Engl J Med 1988; 1999: 341:556-341: 562.
3. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. Pereira BJ, Levey AS, Hepatitis Cvirus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-999.
5. Pereira BJ. Hepatitis C. Infection and post-transplantation liver disease. Nephrol Dial Transplant 1995; 10: 58-67.
6. Schmid CH, Levey AS, Pereira BJ. Hepatitis Cvirus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1999; 56: 700-706.
7. Morales JM, Campistol JM, Castellano G et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47: 236-240,
8. Ali MK, Light JA, Barhyte DY et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998; 66: 1694-1697.
9. Thysell H, Hermodsson S, Blohme I, Hepatitis C. Superinfection in hepatitis C virus (HCV) -infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60: 642-647.
10. Lyra AC, Yusim K, Everhart JE et al. Liver transplantation with hepatitis C virus-infected graft: interaction between donor and recipient viral strains. Hepatology 2003; 38: 25-33.
11. Feray C, Shouval D, Samuel D. Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? Gastroenterology 1999; 117: 263-265.
12. Vargas HE, Laskus T, Wang LF et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117: 149-153.
13. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8: 19-27.
14. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210.
15. Wiesner RH. Long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493-499.
16. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288.
17. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C. controlled trial. J Gastroenterol 2003; 38: 567-572.
18. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. a randomized trial. Lancet 2001; 356: 956-965.